venous thrombosis - direct antithrombins - all type of patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>venous thrombosis</strong> - direct antithrombins </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> RE-COVER, 2009 </a> <br> NCT00291330 </td> <td> dabigatran 150 mg twice daily in a fixed-dose<br>  <i>versus</i> <br> warfarin dose-adjusted to an INR between 2.0 and 3.0 </td> <td> patients with acute venous thromboembolism , treated with low molecular weight or unfractionated heparin for 5 to 11 days </td> <td> follow-up 6 months<br> n=1274/1265<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>RE-COVER, 2009 : </b> Schulman S, Eriksson H, Goldhaber SZ, et al. Dabigatran etexilate versus warfarin in the treatment of venous thromboembolism. Oral presentation, <i>ASH Annual Meeting 2009, Abstract number 19394, 6 December 2009 </i> [PMID ] </p> <p> <b>RE-COVER, 2009 : </b> Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZDabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>N Engl J Med 2009 Dec 10;361:2342-52</i> [PMID 19966341] 10.1056/NEJMoa0906598 </p>